Encouraging data for ViiV’s long-acting, two-drug HIV therapy
ViiV Healthcare has unveiled encouraging mid-stage data backing a long-acting formulation of its two-drug regimen cabotegravir and rilpivirine for the treatment of HIV.
Read More
Tag: long-acting
ViiV trials long-acting, two-drug HIV regimen
ViiV Healthcare has kicked off a late-stage study testing a long-acting, two-drug regimen of its cabotegravir and Janssen’s rilpivirine in virally suppressed adults with HIV-1 infection
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
